Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06407635 · ClinicalTrials.gov registry record · Phase 1
A Study of Psilocybin for PTSD
A Phase 1 study of Post Traumatic Stress Disorder, sponsored by Johns Hopkins University.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06407635: Active Phase 1 study of Post Traumatic Stress Disorder, sponsored by Johns Hopkins University.
NCT06407635 is a Phase 1 study of Post Traumatic Stress Disorder that is active but no longer recruiting, run by Johns Hopkins University. The registered enrollment target is 20 participants, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06407635, a Phase 1 study of Post Traumatic Stress Disorder, is active but no longer recruiting, sponsored by Johns Hopkins University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The proposed open-label, controlled study at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) will test the following primary hypotheses in adult patients with chronic PTSD who are currently taking a serotonin reuptake inhibitor: psilocybin therapy will be feasible and safe for participants, significantly remediate PTSD symptoms, and enhance wellbeing and quality of life. In addition, the study will examine whether elements of evidence-based trauma-focused psychotherapy enhance treatment response when paired with psilocybin.
Primary Outcome
Adverse event monitoring throughout the study.
Conditions Studied
Interventions
- DRUG Psilocybin
- OTHER Trauma-focused psychotherapy
- OTHER Standard psychological support
Study Locations (1)
Maryland
- Johns Hopkins Center for Psychedelic and Consciousness Research - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-06-07 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
What the registry record for NCT06407635 still lists
NCT06407635 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 664-participant average among 262 other Post Traumatic Stress Disorder trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Post Traumatic Stress Disorder appearing as the primary indexed condition, and to 3 interventions - of which Psilocybin is the first listed.
NCT06407635 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT06407635 about?
NCT06407635 is a clinical study titled "A Study of Psilocybin for PTSD". The proposed open-label, controlled study at the Johns Hopkins Center for Psychedelic and Consciousness Research (CPCR) will test the following primary hypotheses in adult patients with chronic PTSD who are currently taking a serotonin reuptake inhibitor: psilocybin therapy will be feasible and safe...
What is the current status of trial NCT06407635?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-06-07. Estimated completion is 2027-05.
What conditions does trial NCT06407635 study?
This clinical trial studies the following conditions: Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT06407635?
The interventions under investigation include: Psilocybin (DRUG), Trauma-focused psychotherapy (OTHER), Standard psychological support (OTHER).
Who is sponsoring clinical trial NCT06407635?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06407635 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Traumatic Stress Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06407635's enrollment target sits among peer trials
20 231st of 262 higher than 22 of 262 other Post Traumatic Stress Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Post Traumatic Stress Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
RECRUITING · Phase 1
-
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)
RECRUITING · Phase 1
-
Mitigating PTSD-CUD After Sexual Assault
RECRUITING · Phase 1
-
Biological Signatures, Probiotic Among Those With mTBI and PTSD
COMPLETED · Phase 1
-
Cannabidiol as a Treatment for AUD Comorbid With PTSD
COMPLETED · Phase 1
-
Virtual Reality (VR) Therapy for Post-Traumatic Stress Disorder (PTSD)
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI